financetom
Business
financetom
/
Business
/
Fair Isaac Q1 Non-GAAP EPS, Revenue Increase; Reiterates 2025 Outlook
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Fair Isaac Q1 Non-GAAP EPS, Revenue Increase; Reiterates 2025 Outlook
Feb 4, 2025 1:57 PM

04:37 PM EST, 02/04/2025 (MT Newswires) -- Fair Isaac ( FICO ) reported fiscal Q4 non-GAAP earnings late Wednesday of $5.79 per diluted share compared with $4.81 a year ago.

Analysts polled by Factset expected $6.09.

Revenue in the quarter ended Dec. 31 was $440 million compared with $382.1 million a year ago.

Analysts expected $452.2 million.

For 2025, the consumer credit reporting company reiterated its prior forecast looking for non-GAAP EPS of $28.58 on $1.98 billion in revenue.

Analysts are expecting $29.33 and $2 billion, respectively.

FICO shares fell more than 4% in after-hours trading.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
What's Going On With Bitcoin Mining Stock Marathon Digital Monday?
What's Going On With Bitcoin Mining Stock Marathon Digital Monday?
Aug 12, 2024
Marathon Digital Holdings Inc ( MARA ) shares are trading lower. The company on Monday announced a proposed private offering of convertible senior notes. What Happened: Bitcoin (CRYPTO: BTC) mining company Marathon Digital ( MARA ) said it intends to offer $250 million worth of convertible senior notes due 2031 in a private offering to institutional buyers. The company expects...
EnLink Midstream to Launch Senior Notes Offering
EnLink Midstream to Launch Senior Notes Offering
Aug 12, 2024
09:25 AM EDT, 08/12/2024 (MT Newswires) -- EnLink Midstream ( ENLC ) said Monday that it plans to launch an offering of senior notes. The midstream energy company said it plans to use the net proceeds to repay borrowings under its revolving credit facility, as well as an accounts receivable securitization facility. EnLink said the offering will be fully guaranteed...
ImmunityBio Says Anktiva Now Available Under US Commercial, Government Insurance Plans
ImmunityBio Says Anktiva Now Available Under US Commercial, Government Insurance Plans
Aug 12, 2024
09:25 AM EDT, 08/12/2024 (MT Newswires) -- ImmunityBio ( IBRX ) said Monday that Anktiva is now available for patients under both commercial and government insurance plans in the US. The US Food and Drug Administration approved Anktiva, the company's immunotherapy to treat Bacillus Calmette-Guerin-unresponsive non-muscle invasive bladder cancer, in April. Additionally, ImmunityBio ( IBRX ) has started the filing...
Wave Life Sciences' Duchenne MD Treatment Candidate Gets US FDA Rare Pediatric Disease Designation
Wave Life Sciences' Duchenne MD Treatment Candidate Gets US FDA Rare Pediatric Disease Designation
Aug 12, 2024
09:26 AM EDT, 08/12/2024 (MT Newswires) -- Wave Life Sciences ( WVE ) said Monday the US Food and Drug Administration has given rare pediatric disease designation to its drug candidate WVE-N531 to treat boys with Duchenne muscular dystrophy who are amenable to exon 53 skipping. The drug is being assessed in a trial that enrolled 11 boys with the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved